NewAmsterdam Pharma director exercises warrants, trust sells shares

NewAmsterdam Pharma director Louis G. Lange reported a mix of warrant exercises and share sales.

Rhea-AI Filing Summary

NewAmsterdam Pharma director Louis G. Lange reported a mix of warrant exercises and share sales. On March 9, 2026, he exercised warrants to acquire 44,619 Ordinary Shares at $11.50 per share, leaving him with 54,979 Ordinary Shares held directly.

Separately, on March 6, 2026, a trust associated with him, the LGLange III Trust DTD10, sold 28,186 Ordinary Shares in open-market transactions at a weighted average price of $29.41 per share, within a range of $29.03 to $29.68, and reported no remaining indirect holdings.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider LANGE LOUIS G

Role Director

Sold 28,186 shs ($829K)

Approx. gross sale proceeds $829K

Approx. exercise cost $513K

Type	Security	Shares	Price	Value
In-the-Money Exercise	Warrant (right to buy)	44,619	$0.00	$0.00
In-the-Money Exercise	Ordinary Shares	44,619	$11.50	$513K
Sale	Ordinary Shares	28,186	$29.41	$829K

Holdings After Transaction: Warrant (right to buy) — 0 contracts (Direct); Ordinary Shares — 0 shares (Indirect, See footnote); Ordinary Shares — 54,979 shares (Direct)

Footnotes (2)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.03 per share to $29.68 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
2. F2. The shares are held directly by LGLange III Trust DTD10 (the "Trust") for the benefit of the Reporting Person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did NewAmsterdam Pharma (NAMS) director Louis G. Lange report?

Louis G. Lange reported both an option-like exercise and a sale. He exercised warrants to acquire 44,619 Ordinary Shares at $11.50 per share, then a related trust sold 28,186 Ordinary Shares in open-market trades at a weighted average price of $29.41 per share.

How many NewAmsterdam Pharma (NAMS) shares did Louis G. Lange acquire through warrant exercise?

Lange exercised warrants for 44,619 Ordinary Shares. The warrants had an exercise price of $11.50 per share. Following this in-the-money derivative exercise, his direct ownership in NewAmsterdam Pharma increased to a reported 54,979 Ordinary Shares as of the transaction date.

How many NewAmsterdam Pharma (NAMS) shares were sold by the LGLange III Trust?

The LGLange III Trust DTD10 sold 28,186 Ordinary Shares. These open-market sales occurred on March 6, 2026 at a weighted average price of $29.41 per share, with individual trades ranging from $29.03 to $29.68, leaving no reported remaining indirect holdings.

What prices were received in the NewAmsterdam Pharma (NAMS) insider share sales?

The reported weighted average sale price was $29.41 per share. According to the filing, the 28,186 Ordinary Shares sold by the LGLange III Trust DTD10 were executed in multiple transactions at prices between $29.03 and $29.68 per share in the open market.

What is Louis G. Lange’s reported NewAmsterdam Pharma (NAMS) shareholding after these transactions?

Lange reported holding 54,979 Ordinary Shares directly after exercising warrants. The Form 4 also shows that the LGLange III Trust DTD10, which previously held shares indirectly for his benefit, reported zero Ordinary Shares remaining following the March 6, 2026 open-market sales.

Were the NewAmsterdam Pharma (NAMS) insider sales made directly by Louis G. Lange?

The sale was executed by the LGLange III Trust DTD10. The filing notes that the 28,186 Ordinary Shares were held and sold by this trust, which is described as being for Lange’s benefit, while his warrant exercise and resulting holdings are reported as direct ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/10/2026 - 08:58 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LANGE LOUIS G

(Last) (First) (Middle)

C/O NEWAMSTERDAM PHARMA COMPANY N.V.

GOOIMEER 2-35

(Street)

NAARDEN P7 1411 DC

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NewAmsterdam Pharma Co N.V. [ NAMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	03/06/2026		S		28,186	D	$29.41(1)	0	I	See footnote(2)
Ordinary Shares	03/09/2026		X		44,619	A	$11.5	54,979	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant (right to buy)	$11.5	03/09/2026		X			44,619	12/22/2022	11/23/2027	Ordinary Shares	44,619	$0	0	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.03 per share to $29.68 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

2. The shares are held directly by LGLange III Trust DTD10 (the "Trust") for the benefit of the Reporting Person.

	/s/ Louise Kooij by Power of Attorney from Louis G. Lange	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.